Management of Abnormal Cervical Screening Results

Rationale for Colposcopy

• The American Society for Colposcopy and Cervical Pathology recommends immediate colposcopy as the preferred management approach for a female with abnormal cervical screening results and positive HPV test, due to the significant risk of underlying high-grade cervical intraepithelial neoplasia (CIN) 1, 2, 3
• HPV-positive abnormal cervical screening results in adult women carries a significant risk of underlying high-grade CIN, necessitating colposcopic evaluation, with a risk of high-grade histological changes (CIN 2 or higher) typically detected in less than 12% of cases, but significantly higher when HPV is positive 1, 2, 3
• The National Comprehensive Cancer Network recommends colposcopy as the preferred management for HPV-positive abnormal cervical screening results in women over 30 years of age, with a higher risk of underlying significant disease 2, 3

Management Algorithm

• The American College of Obstetricians and Gynecologists recommends immediate colposcopy as the initial step in managing abnormal cervical screening results with positive HPV test, with subsequent management depending on colposcopy and biopsy findings 2
• If colposcopy is satisfactory, and CIN 2 or higher is detected, the American Society for Colposcopy and Cervical Pathology recommends proceeding with appropriate treatment (ablative or excision procedure), with a follow-up plan in place 2
• If colposcopy is unsatisfactory, the National Comprehensive Cancer Network recommends performing endocervical curettage (ECC) and cervical biopsy, with management according to findings 2

Evidence Strength and Considerations

• The recommendation for colposcopy in HPV-positive abnormal cervical screening results is based on strong consensus guidelines (ASCCP), with studies showing that HPV testing has higher sensitivity (88-90%) but lower specificity (72-79%) than cytology alone for detecting high-grade lesions 3
• The American Cancer Society notes that the prevalence of CIN 3 or higher in screening populations is approximately 3.2%, but risk increases significantly with HPV-positive abnormal cervical screening results 2

Important Considerations for This Patient

• At age 55, this patient is in a demographic where HPV positivity is more concerning and less likely to represent transient infection, with a higher risk of underlying significant disease 2
• The American Society for Colposcopy and Cervical Pathology recommends that HPV positivity with abnormal cervical screening results in women aged 30 years and older carries a higher risk of underlying significant disease, with HPV types 16 and 18 carrying the highest risk (17% and 14% respectively for CIN 3+), compared to 3% for other high-risk types 2

Common Pitfalls to Avoid

• The National Comprehensive Cancer Network recommends not delaying colposcopy in HPV-positive abnormal cervical screening results cases in women over 30, as this increases the risk of missed high-grade disease 3
• The American College of Obstetricians and Gynecologists recommends not relying on repeat cytology alone for HPV-positive abnormal cervical screening results in this age group, as it has lower sensitivity (76.2%) compared to immediate colposcopy 2
• The American Society for Colposcopy and Cervical Pathology recommends not assuming low risk despite abnormal cervical screening results being a relatively mild cytologic abnormality; the combination with HPV positivity significantly increases risk 1, 2
• The National Comprehensive Cancer Network recommends not performing HPV genotyping before colposcopy in women with abnormal cervical screening results who are already HPV-positive, as colposcopy is indicated regardless of HPV type 2

Management of Abnormal Cervical Screening Results

Rationale for Immediate Colposcopy

• The combination of ASCUS cytology with HPV positivity significantly elevates the risk of underlying high-grade cervical intraepithelial neoplasia (CIN 2+), warranting immediate colposcopic evaluation rather than surveillance, as recommended by the Centers for Disease Control and Prevention (CDC) 4
• Women with ASCUS cytology and positive high-risk HPV testing should proceed directly to colposcopy, as recommended by the American Society for Colposcopy and Cervical Pathology (ASCCP) 4

Management Algorithm

• If CIN 1 or less is detected, follow surveillance protocols with repeat HPV testing or co-testing at 1 year, as recommended by the CDC 4
• If no lesion is identified, repeat HPV testing with or without concurrent Pap test in 1 year, as recommended by the CDC 4

Evidence Quality Note

• The recommendation for immediate colposcopy is based on strong consensus from the 2019 ASCCP Risk-Based Management Guidelines and 2021 CDC STI Treatment Guidelines, both of which supersede older "repeat testing" approaches, with a strength of evidence considered high 4

Management of ASCUS with Positive HPV

Primary Management Approach

• The American College of Obstetricians and Gynecologists recommends proceeding directly to colposcopy for all women with ASCUS and positive high-risk HPV, as this combination significantly elevates the risk of underlying high-grade cervical intraepithelial neoplasia (CIN 2+), with approximately 20% risk of CIN2+ and 9.7% risk of CIN3+ in this population 5

Follow-up Options

• The American College of Obstetricians and Gynecologists recommends two acceptable follow-up options after negative colposcopy: HPV DNA testing at 12 months or repeat cytology at 6 and 12 months, with the 12-month HPV testing approach demonstrating 92.2% sensitivity and a 55% referral rate back to colposcopy 5, 6

Special Considerations

• The American College of Obstetricians and Gynecologists recommends against delaying colposcopy based on age considerations, and all women with ASCUS who are positive for any high-risk HPV should proceed to colposcopy regardless of specific HPV type 5
• The American College of Obstetricians and Gynecologists recommends against performing HPV 16/18 genotyping before colposcopy, as colposcopy is indicated for all high-risk HPV types in this context 5
• For pregnant women, management is identical to non-pregnant women over age 20, except colposcopy may be deferred until at least 6 weeks postpartum, and endocervical curettage is contraindicated in pregnancy 5
• For immunosuppressed women, including HIV-infected women, management should be identical to the general population with immediate colposcopy for HPV-positive ASCUS 5

Management of HPV-Positive Test Results

Immediate Next Steps

• The Centers for Disease Control and Prevention recommends ordering reflex cytology from the same specimen if still available, or having the patient return for cytology testing to guide appropriate management, as primary HPV testing is used for screening, with cytology testing performed for all positive HPV test results 7

Management Algorithm Based on Cytology Results

• For patients with high-grade squamous intraepithelial lesions (HSIL) on cytology, the Centers for Disease Control and Prevention recommends proceeding directly to colposcopy with consideration for expedited treatment for non-pregnant patients aged ≥25 years 7
• For patients with HSIL on cytology, colposcopy with biopsy is an acceptable alternative if preferred after shared decision-making 7

Risk Stratification Considerations

• Analysis from the ALTS trial showed that HPV-positive ASC-US and LSIL carry equal 26% cumulative risk of CIN2-3 over 2 years, according to the National Comprehensive Cancer Network 8, 9

Common Pitfalls to Avoid

• The Centers for Disease Control and Prevention recommends not proceeding directly to colposcopy without knowing cytology results unless it is infeasible for the patient to return for cytology testing alone, in which case colposcopy can be considered 7
• The Centers for Disease Control and Prevention recommends not delaying obtaining cytology results as this represents incomplete screening that cannot be properly managed according to current guidelines 7
• The Centers for Disease Control and Prevention recommends not ordering HPV genotyping before obtaining cytology as the cytology result is the primary determinant of immediate management 7

HPV‑Based Triage and Management of ASC‑US on Pap Smear

Initial Triage Strategy

• Reflex high‑risk HPV DNA testing is the preferred initial triage for ASC‑US, with immediate colposcopy when the test is positive. The American Society for Colposcopy and Cervical Pathology (ASCCP) recommends this approach based on strong consensus guidelines. 10 Strength: Strong consensus.

• In adult women (≥ 21 years), reflex HPV testing identifies approximately 9.7 % of patients who have underlying CIN 2+ while sparing HPV‑negative women from unnecessary colposcopy. 10

• When HPV testing is unavailable, immediate colposcopy can be used but results in a higher referral rate (~ 39 %) compared with HPV‑triage (16.9‑29.4 %). 10

• If HPV testing is unavailable, repeat cytology at 6 months and 12 months is an acceptable alternative; colposcopy is performed if either follow‑up smear shows ASC‑US or a higher‑grade abnormality. [10][11]

Age‑Specific Recommendations

• Women aged 21‑29 years: Follow the standard HPV‑triage algorithm (reflex HPV testing, colposcopy if positive). Guideline: ASCCP. 11

• Adolescents and women < 21 years:

  • HPV testing is not recommended because of the high prevalence of transient infections.
  • Repeat cytology at 12 months is the preferred management; if ASC‑US or LSIL persists, repeat again at 24 months.
  • Colposcopy is reserved for ASC‑H, HSIL, or persistent abnormality after 3 years. Guideline: ASCCP. 11

Post‑Colposcopy Follow‑Up

• If colposcopy is negative or shows only CIN 1, repeat cytology at 6 months and 12 months until two consecutive negative results are obtained. 10

• If colposcopy is unsatisfactory, perform endocervical curettage (ECC) and cervical biopsy. 11

• During pregnancy, endocervical curettage is contraindicated. 10

Evidence Basis

• The recommendation for HPV triage is grounded in strong consensus guidelines from ASCCP and the ASCUS‑LSIL Triage Study (ALTS), which demonstrated that HPV testing is at least as sensitive as immediate colposcopy for detecting CIN 3 while referring roughly half as many women to colposcopy. Strength: Strong consensus. 11

Management of ASC‑US with Negative HPV Testing (cited evidence)

Guideline Recommendations

• The American Society for Colposcopy and Cervical Pathology (ASCCP) recommends that women with ASC‑US and a negative high‑risk HPV test do not require immediate colposcopy or accelerated follow‑up, because their risk of high‑grade disease is comparable to that of women with completely normal screening results. 12

• ASCCP advises that repeat HPV testing should not be performed before the next routine screening interval, as transient cytologic abnormalities without HPV do not merit earlier surveillance. This guidance is based on consensus recommendations for adult women (≥21 years). 13

Diagnostic Test Performance

• HPV testing used as a triage tool for ASC‑US demonstrates 92 % sensitivity for detecting CIN 2+ lesions, confirming its reliability for risk stratification in this context. 12

Evidence Basis

• The recommendation to forgo immediate colposcopy is supported by strong consensus guidelines from ASCCP and reinforced by the ASCUS‑LSIL Triage Study (ALTS), which established HPV triage as the gold‑standard approach for managing ASC‑US. This constitutes Level 1 evidence. 13

• The same ALTS data underline that adolescent‑type management protocols (which avoid HPV testing) should not be applied to adult women, because HPV triage provides highly informative risk assessment for women aged ≥ 21 years. 13

Cervical Cancer Screening Intervals for Women Aged 30‑65

Recommended Screening Intervals

• The American Cancer Society recommends that women 30‑65 years old be screened every 5 years with HPV + Pap co‑testing (preferred) or every 3 years with Pap testing alone (acceptable). 14
• When both HPV testing and cytology are negative, the combined result provides the lowest risk, allowing a 5‑year screening interval. 15, 16
• If Pap testing is performed without HPV co‑testing, the maximum safe interval is 3 years. 14, 16

Management After ASC‑US with Negative HPV

• Women with ASC‑US and a negative high‑risk HPV test should return to routine screening intervals: 3 years if only Pap is used, or up to 5 years if co‑testing is planned. 14, 16
• For women ≥ 30 years with a negative HPV result, rescreening should not occur before 3 years, and intervals should not exceed the guideline‑recommended limits. 15, 16

Overdue Screening Example

• A 48‑year‑old woman who had ASC‑US with a negative HPV test four years ago is now overdue for screening and should be screened immediately. 14, 16

Non‑Cervical Pathology Does Not Influence Screening

• Findings from an endometrial biopsy (e.g., benign endometrial hyperplasia) are irrelevant to cervical cancer screening timing. 14
• Cervical cancer screening addresses cervical pathology only; endometrial conditions do not increase cervical cancer risk nor alter screening recommendations. 14

Immediate Action and Follow‑up

• Schedule immediate cervical cancer screening using HPV + Pap co‑testing (preferred) or Pap alone. 14
• If the co‑test is negative, the next screening can be performed in 5 years; if Pap alone is negative, the next screening should be in 3 years. 14
• Continue routine screening until age 65. Screening may be discontinued when a woman has ≥ 3 consecutive negative Pap tests or ≥ 2 consecutive negative co‑tests within the past 10 years, with the most recent test within the last 5 years. 14

Management of ASC‑US Cervical Cytology Findings

Prevalence and Clinical Significance

• Approximately 4 % of all Pap smears are reported as ASC‑US, and about 9.7 % of these cases harbor underlying high‑grade cervical intra‑epithelial neoplasia (CIN 2 or greater), indicating the need for careful triage. 17

Initial Triage with High‑Risk HPV Testing

• Reflex testing for high‑risk HPV DNA on the ASC‑US specimen is the preferred initial triage strategy for adult women; it efficiently identifies the ~9.7 % of patients with CIN 2 + while sparing HPV‑negative women from unnecessary colposcopy. 17

Management of HPV‑Positive ASC‑US

• Women with ASC‑US and a positive high‑risk HPV result should undergo immediate colposcopy with directed biopsy, because this combination confers an approximately 20 % risk of CIN 2 + and a 9.7 % risk of CIN 3 +. 17
• If colposcopy confirms CIN 2 (or higher), appropriate treatment—either ablative therapy or excisional procedure—should be performed. 17
• When colposcopy is satisfactory and shows only CIN 1 or is negative, follow‑up includes repeat cytology at 6 months and 12 months (or HPV testing at 12 months); colposcopic reevaluation is indicated if HPV remains positive or cytology progresses to ASC‑US or a higher‑grade abnormality. 17

Management of HPV‑Negative ASC‑US

• Women with ASC‑US and a negative high‑risk HPV test do not require immediate colposcopy; their risk of high‑grade disease is comparable to that of women with completely normal screening results. 17
• These patients should return to routine screening intervals: every 3 years if only Pap testing is used, or every 5 years if HPV co‑testing is planned for women aged 30–65 years. 17

Alternative Management When HPV Testing Is Unavailable

• If high‑risk HPV testing cannot be performed, repeat cytology at 6 months and 12 months is an acceptable alternative; colposcopy should be performed if either follow‑up smear shows ASC‑US or a higher‑grade abnormality. 17
• Immediate colposcopy without prior HPV triage is also permissible, but it results in a higher referral rate and is less efficient than HPV‑guided triage. 17

Special Considerations in Pregnancy

• Endocervical curettage is contraindicated during pregnancy; management otherwise follows the same algorithm as for non‑pregnant women over age 20. 17

Management of HPV‑Negative ASCUS and Incidental Candida in Young Women

Cervical Screening Recommendations

• The American Society for Colposcopy and Cervical Pathology (ASCCP) 2006 consensus guidelines recommend that women > 20 years old with HPV‑negative ASCUS undergo repeat cytology in 12 months rather than immediate colposcopy, reflecting a low risk of high‑grade disease. 18
• For a 21‑year‑old woman with HPV‑negative ASCUS, routine annual cytology (Pap smear) is appropriate, and the incidental Candida finding should be treated only if the patient reports vulvovaginal symptoms. 18

HPV Testing Intervals

• Guidelines explicitly state that repeat HPV testing should not be performed before 12 months after an initial negative result, to avoid unnecessary testing and false‑positive results. 18

Avoidance of Unnecessary Procedures

• Colposcopy is not indicated for HPV‑negative ASCUS because the negative predictive value for CIN 3+ over the next two years approaches 99.7–100 %; therefore, referral for colposcopy would constitute overtreatment. 18

Follow‑up Scheduling

• The patient should be scheduled for a routine annual Pap smear at age 22 (12 months from the current visit). 18

Management of ASCUS with Negative High‑Risk HPV in Women Aged 30–65 Years

Primary Recommendation

• The National Comprehensive Cancer Network (NCCN) recommends that a 33‑year‑old woman with ASCUS and a negative high‑risk HPV test return to routine co‑testing (Pap + HPV) in 3 years and does not require immediate colposcopy or accelerated follow‑up. [19][20]21

Follow‑up Interval

• NCCN updates specify a 3‑year co‑testing interval for HPV‑negative ASCUS in women 30–65 years, replacing the earlier 5‑year interval used for completely negative co‑tests. [19][20]21

Alternative Follow‑up When Co‑Testing Is Unavailable

• If HPV testing cannot be performed, a repeat Pap test alone in 3 years is an acceptable surveillance strategy. [22][23]

Age‑Specific Considerations

• For women ≥30 years, co‑testing is the preferred primary screening method; a prior ASCUS result (even with negative HPV) shortens the recommended interval to 3 years rather than the standard 5‑year interval for routine screening. [19][20][21][22]23

HPV Testing for Triage

• The American Society for Colposcopy and Cervical Pathology (ASCCP) endorses HPV testing as the triage tool for ASCUS in women ≥25 years, because HPV prevalence is lower and more predictive in this age group. 19

Pitfalls to Avoid

• Do not perform HPV 16/18 genotyping in a patient who already has a negative high‑risk HPV result, as it does not change management. [20][21]
• Do not apply the 5‑year screening interval used for completely negative co‑tests to HPV‑negative ASCUS; the appropriate interval is 3 years. [19][20]21

Discontinuation of Screening

• Women cannot exit cervical cancer screening at age 65 based solely on a single HPV‑negative ASCUS result; they must achieve two consecutive negative co‑tests or three consecutive negative Pap tests before cessation is permitted. [19][20]21

Patient Counseling

• Counsel the patient that her short‑term risk of high‑grade disease is very low, but she should return for co‑testing in 3 years because guidelines recognize a modestly higher long‑term cancer risk compared with completely normal screens. [20][21]

HPV Triage and Management of ASC‑US and Incidental Endometrial Cells in Women Aged 21‑29

Initial Triage of ASC‑US

• Reflex high‑risk HPV DNA testing performed on the same liquid‑based cytology specimen is the preferred strategy for women aged 21‑29 with ASC‑US, identifying roughly 9.7 % of patients with underlying CIN 2+ while sparing HPV‑negative women from unnecessary colposcopy. American Society for Colposcopy and Cervical Pathology (ASCCP) – strong consensus [24][25]

• When the reflex HPV test is negative, patients should return to routine screening with repeat cytology in 12 months; the negative predictive value for CIN 3+ approaches 99.7‑100 % over the subsequent two years. ASCCP – strong consensus 25

Management When HPV Testing Is Unavailable

• If reflex HPV testing cannot be performed, repeat cytology every 6 months until two consecutive negative results are obtained; colposcopy is indicated if any repeat smear shows ASC‑US or a higher‑grade abnormality. ASCCP – strong consensus 25

Management of Incidental Endometrial Cells

• The detection of benign endometrial cells on a Pap smear in a young premenopausal woman does not require any additional evaluation, as this finding is considered normal during the first half of the menstrual cycle. ASCCP – strong consensus 24

• The presence of endometrial cells does not modify the management algorithm for concurrent ASC‑US; each abnormality is addressed independently according to its respective guideline. ASCCP – strong consensus 24

Post‑Colposcopy Follow‑up

• If colposcopy reveals CIN 2 or higher, treatment should be undertaken with either ablative therapy or excisional procedure, selected according to disease extent and colposcopic appearance. ASCCP – strong consensus 26

• When colposcopy is negative or shows only CIN 1, follow‑up can be performed with repeat cytology at 6 months and 12 months, or with HPV testing at 12 months. ASCCP – strong consensus [26][25]

• Colposcopic re‑evaluation is warranted if HPV remains positive at 12 months or if repeat cytology demonstrates ASC‑US or a higher‑grade lesion. ASCCP – strong consensus 25

• Persistence of CIN 1 for at least 2 years permits either continued surveillance or definitive treatment, based on patient preference and clinical judgment. ASCCP – strong consensus 26

• In cases of unsatisfactory colposcopy where the transformation zone cannot be fully visualized, endocervical curettage (ECC) is preferred, performed cautiously in young women to minimize the risk of cervical stenosis. ASCCP – strong consensus 25

Common Pitfalls to Avoid

• Routine primary HPV screening is not recommended for women aged 21‑29; HPV testing in this age group should be reserved exclusively for triaging ASC‑US or ASC‑H results because transient infections are common and usually self‑limited. ASCCP – strong consensus [24][25]

• Delay in obtaining reflex HPV results should be avoided; testing must be performed immediately on the same specimen to prevent the need for a separate patient visit. ASCCP – strong consensus 25

• Re‑testing HPV before 12 months after an initial negative result is discouraged, as earlier testing increases false‑positive rates without improving detection of clinically significant disease. ASCCP – strong consensus 25

Evidence Quality and Strength

• The recommendation for HPV triage of ASC‑US is grounded in strong consensus guidelines from the ASCCP and supported by the ASCUS‑LSIL Triage Study (ALTS), which demonstrated that HPV testing is at least as sensitive as immediate colposcopy for detecting CIN 3 while referring roughly half as many women to colposcopy. Level 1 evidence 25

• The 2006 ASCCP consensus guidelines and subsequent updates consistently prioritize HPV‑based triage over repeat cytology or immediate colposcopy for women over age 20 with ASC‑US, representing Level 1 evidence. ASCCP – strong consensus [26][25]